Audit: QRS - Iron for Health & Longevity

Audit conducted on 25/08/2026 05:03 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol values, time-to-effect figures, biomarker targets, gate items and tier lists trace to ER lines 395–415, 454, 484–494 and 333–369.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	The ER contains no empty-state or hedged section requiring verbatim carry-over; tier placement (Low/Speculative) carries the ER’s own strength grading.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindication thresholds (transferrin saturation >45%, ferritin >300/200 ng/mL) and the “no documented deficiency” exclusion are carried at full strength.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	All [stop_items] come from the ER “Populations who should avoid Iron” list; all [caution_items] come from the ER interaction bullets; no Benefit- or Risk-Modifying Factor is surfaced in a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, expert names or brand names appear anywhere in the QRS; named drugs (doxycycline, ciprofloxacin, alendronate, omeprazole, semaglutide) all appear in the ER for the same interaction.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind are present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Neutral, measurement-first framing mirrors the ER Conclusion.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified targets and thresholds throughout, presented without alarm or promotion.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated as facts and ranges, not instructions to an individual.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives; the footer disclaimer is the template’s fixed text.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “should”, “recommend” or “advise” constructions in the populated variables.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are confined to the Monitoring table and gates, where they are the named entities themselves.
2.8	Information is presented in a concise and very compact manner	🟢	Benefits and Risks are bare ER headings; gate items are stripped to the key fact plus qualifier.
2.9	It DOES NOT address the reader directly	🟢	Confirmed: no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional targets (ferritin 50–100/50–150 ng/mL, ALT <25/<20 U/L, HbA1c <5.4%) rather than conventional laboratory cut-offs.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Alternate-day fasted morning dosing, nine-marker panel and liver MRI assume a high-effort audience.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Depth of the Monitoring panel and the genotype-aware contraindications exceed general-population framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The At-A-Glance leads with “measurement, not supplementation, comes first”, inverting the general-population default.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not occur; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal terminology throughout; the plain wording in At-A-Glance is required by item 7.4 and matches the ER’s own Conclusion register.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	A full diff against [qrs_template] shows every fixed heading, gate heading, tier label and column header byte-identical.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 38 template variable names present; marker_#* is instantiated nine times and qualitative_item# six times.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The template diff shows changes confined to the metadata block and checklist-addressed variables; CSS, comments and structural markup are unchanged.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section mapped to the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard repletion protocol”, “Baseline biomarkers guide dose” and “Best time of day” are the ER’s bold labels verbatim (ER lines 395, 415, 403); all nine Monitoring row labels match the ER biomarker table verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Action and marker labels are verbatim; the Time-to-Effect labels name the ER’s own listed measures (hemoglobin, fatigue, ferritin) from ER line 454.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji present; the ER’s “⚠️ Conflicted” markers were stripped from the benefit and risk headings.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Condensation is applied throughout: 14 ER interaction bullets merged to 11 items, definitional glosses stripped from contraindications, Benefits/Risks reduced to bare headings, qualitative items trimmed.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the preceding descriptive text sits before the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in the header, footer or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly so because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: iron_2026-0825-0200_Opus_ER.md, matching the ER frontmatter filename.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0825-0449.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” = nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: iron_2026-0825-0200_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: Iron for Health & Longevity - Quick Reference Sheet, with the ampersand correctly encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: Iron for Health & Longevity, matching ER frontmatter canonical_topic.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 08/25/2026, correctly derived from 2026-0825.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header carries only the title and the template’s fixed subline; the ER’s “Also known as” list was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses ER lines 527–531 into benefit scope, accumulation cost and the measurement-first action.
7.2	[at_a_glance] is no longer than 60 words	🟢	57 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Anemia reversal, fatigue, restless legs and heart-failure admission from ER line 527; liver damage, joint replacement, diabetes and shorter life from line 529; the no-excretion premise from line 527.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “anemia”, “restless legs”, “heart failure” and “diabetes” are lay-familiar terms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years or sample sizes; “in genetic studies” is a generic descriptor carried from the ER Conclusion.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric effect estimates of any kind.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Sourced from the “Populations who should avoid Iron” list at ER lines 361–369.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All seven ER exclusion bullets are present, in ER order.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven <li> elements at lines 542–548.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Definitional glosses stripped (sideroblastic anemia, hemosiderosis, porphyria cutanea tarda) and the trailing “since no benefit above applies without one” removed; no dash-trailing clauses remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Thresholds preserved in full at line 543: transferrin saturation above 45%, ferritin above 300 ng/mL (men) / 200 ng/mL (women), with inflammation excluded.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in its contraindication list.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER identifies seven such populations and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Sourced from the interaction bullets at ER lines 333–359.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All 14 ER interaction bullets are represented across 11 merged items; no item duplicates a contraindication.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eleven <li> elements at lines 556–566.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Chelation and pH mechanisms, drug-class glosses and monitoring instructions all stripped; en-dashes appear only inside numeric ranges.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drugs retained for every class that has them, the “severe” class retained for the antibiotics, and separation windows (4 h, 2–6 h, 2–3 h, 2 h) plus the 200–250 mg donation loss all carried.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in its interaction list.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER identifies 14 interactions and the section is correspondingly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells trace to the ER “Therapeutic Protocol” section at lines 395, 403 and 415.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose and schedule, the biomarker thresholds that set the dose, and timing of administration — the three decision-bearing bullets among the ER’s twelve.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER provides twelve protocol bullets and all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine cells populated; no placeholder text remains.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Hemoglobin, fatigue improvement and ferritin, taken from the ER “Time to effect” bullet at line 454, with the reticulocyte figure folded into [time_1_sub].
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Hemoglobin (anemia correction, High tier) first, fatigue improvement (High tier) second, ferritin (the store-repletion retest gate) third.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER lists four distinct time-to-effect measures and all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine cells populated; 2–4 weeks, 6–12 weeks and 8–12 weeks all match ER line 454.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information at line 454.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Every item is an ER benefit heading from lines 159–217.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated at lines 521–532.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items are the bare ER headings; no magnitudes, confidence intervals or study references carried through.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers have items in the ER, so no span needed hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Every item is an ER risk heading from lines 241–311.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated at lines 578–589; all eleven ER risk headings are represented.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items are the bare ER headings with the “⚠️ Conflicted” markers removed; no odds ratios, incidence figures or study names carried through.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers have items in the ER, so no span needed hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Table rows and cadence trace to the ER “Monitoring Protocol & Defining Success” section at lines 482–494.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER biomarkers present: ferritin, transferrin saturation, hemoglobin, C-reactive protein, mean corpuscular volume, soluble transferrin receptor, alanine aminotransferase, HbA1c and liver iron by magnetic resonance imaging; targets and rationales match the ER table verbatim.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 708 carries the ER’s cadence at line 482: complete blood count at 4 weeks, ferritin and transferrin saturation at 8–12 weeks, then every 6–12 months, with indefinite annual testing for the named groups.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Sourced from the qualitative marker list at ER lines 496–503.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers present at lines 717–732, in ER order.

Issues 25/08/2026 05:03

Pass rate 100.00%. No issues found.

Issues 25/08/2026 04:57

1. 1.1 — Two-hour window applied to minerals: The merged item “Antacids, calcium carbonate, and calcium, zinc or magnesium supplements (2 h separation)” (line 560) carries the antacid bullet’s two-hour window onto the calcium/zinc/magnesium supplements group, for which the ER specifies only “Iron is taken at a different time of day” (ER line 349).
2. 1.2 — Genetic-studies hedge dropped: The At-A-Glance (line 433) states that climbing stores track with “diabetes and a shorter life”, dropping the ER Conclusion’s hedge “and, in genetic studies, a shorter life” (ER line 529).

Fixes 25/08/2026 04:57

1. 1.1 — Two-hour window applied to minerals: Split the merged interaction item into “Antacids and calcium carbonate (2 h separation); calcium, zinc or magnesium supplements (different time of day)” so each group carries the separation window the ER actually specifies for it.
2. 1.2 — Genetic-studies hedge dropped: Restored the ER Conclusion’s hedge in the At-A-Glance, changing “diabetes and a shorter life” to “diabetes and, in genetic studies, a shorter life” (57 words, still within the 60-word budget).